Opportunity Information: Apply for RFA AG 22 001
The grant opportunity "Limited Competition: National Institute on Aging (NIA) Late Onset of Alzheimers Disease (LOAD) Family-Based Study (FBS) (U24 Clinical Trial Not Allowed)" (Funding Opportunity Number RFA-AG-22-001) is a National Institutes of Health (NIH) cooperative agreement designed to strengthen and extend the infrastructure behind a major genetics resource focused on late-onset Alzheimer disease and related dementias. It sits within the Department of Health and Human Services under NIH, and it is tied closely to the Alzheimers Disease Sequencing Project (ADSP), a large, coordinated effort that uses genomic sequencing to discover genetic variants that influence risk for Alzheimer disease and Alzheimer disease-related dementias (AD/ADRD). Rather than funding a typical hypothesis-driven research project, this announcement is focused on building and operating the practical systems needed to keep a family-based cohort productive and expanding over time.
The core purpose is to support the collection and management of high-value family-based data and biospecimens from families in which multiple relatives are affected by Alzheimer disease and related dementias. These multiply affected families are especially valuable for genetic discovery because patterns of disease across relatives can help researchers identify inherited risk factors, interpret rare variants, and refine signals that might be harder to detect in unrelated case-control datasets. The FOA emphasizes expanding the existing NIA Late Onset of AD Family Based Study sample set, meaning the funded group is expected to add more informative relatives and deepen the overall dataset rather than starting from scratch.
A central feature of the work is infrastructure for data collection and longitudinal follow-up. That includes maintaining the operational capability to contact and re-contact participants, track outcomes over time, and update clinical and cognitive information as participants age and as new diagnoses or changes in status occur. Longitudinal follow-up matters here because Alzheimer disease develops over many years, and repeated measurements can help distinguish early signals, progression patterns, and differences between Alzheimer disease and other dementia syndromes. The FOA also calls out ascertainment of antecedent risk factors, which generally refers to capturing exposures and characteristics that occur before dementia onset and may influence risk or resilience, such as medical history, cardiovascular and metabolic factors, lifestyle variables, and other relevant background information. Collecting these kinds of data strengthens the ability of the broader ADSP community to study gene-environment interplay and to interpret genetic findings in a richer clinical context.
Another explicit objective is the characterization of additional relatives from the multiply affected families. In practical terms, that means identifying and enrolling more family members beyond the original participants, gathering pedigree information, documenting affected and unaffected status, and ensuring that the accompanying phenotypic information is detailed enough to be useful for genetic analyses. Adding unaffected relatives can be just as important as adding affected relatives, because unaffected older individuals in high-risk families may help identify protective factors and improve segregation analyses within pedigrees. The overall expectation is that these efforts will enhance the quality, completeness, and analytic value of the family-based resource that feeds into ADSP sequencing and downstream analyses.
Mechanistically, this is a cooperative agreement (U24), which typically means there is substantial NIH programmatic involvement in guiding priorities, coordinating activities, and ensuring that the infrastructure aligns with broader program goals and data standards. The title also states "Clinical Trial Not Allowed," signaling that the award is not intended to support interventional clinical trial activities; the scope is infrastructure and observational follow-up rather than testing treatments or assigning interventions.
This was a limited competition opportunity, meaning it was restricted to a defined set of eligible applicants described in the full announcement (the listing notes "Others" with clarification in the eligibility text). The program fell under the health activity category and a CFDA listing of 93.866. The FOA was created on December 14, 2020, with an original closing date of February 17, 2021. NIH anticipated making one award, with an award ceiling of $2,400,000, indicating a single, relatively substantial infrastructure award intended to support a coordinated national resource rather than multiple small independent projects.
In summary, RFA-AG-22-001 was aimed at sustaining and expanding the operational backbone for the NIA late-onset Alzheimer family-based cohort that supports the ADSP. The funded effort would be expected to keep the cohort engaged over time, broaden participation within informative families, collect and update high-quality clinical and risk factor data, and ensure that these expanded family resources are positioned to accelerate genetic discovery and related analyses across the Alzheimer research community.Apply for RFA AG 22 001
- The Department of Health and Human Services, National Institutes of Health in the health sector is offering a public funding opportunity titled "Limited Competition: National Institute on Aging (NIA) Late Onset of Alzheimers Disease (LOAD) Family-Based Study (FBS) (U24 Clinical Trial Not Allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.866.
- This funding opportunity was created on Dec 14, 2020.
- Applicants must submit their applications by Feb 17, 2021. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $2,400,000.00 in funding.
- The number of recipients for this funding is limited to 1 candidate(s).
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is the name of this grant opportunity?
The opportunity is titled "Limited Competition: National Institute on Aging (NIA) Late Onset of Alzheimers Disease (LOAD) Family-Based Study (FBS) (U24 Clinical Trial Not Allowed)."
What is the Funding Opportunity Number (FON)?
The Funding Opportunity Number is RFA-AG-22-001.
Which federal agency is offering this opportunity?
This is a National Institutes of Health (NIH) funding opportunity within the U.S. Department of Health and Human Services (HHS), and it is associated with the National Institute on Aging (NIA).
What type of award mechanism is used?
The mechanism is a cooperative agreement (U24), which typically involves substantial NIH programmatic involvement to help guide priorities, coordination, and alignment with program goals and standards.
What is the main goal of this funding opportunity?
The main goal is to strengthen and extend the infrastructure supporting a major family-based genetics resource focused on late-onset Alzheimer disease (LOAD) and related dementias, so the resource remains productive and can expand over time.
Is this a typical hypothesis-driven research grant?
No. The announcement is focused on building and operating practical systems and infrastructure (data, biospecimens, operations, follow-up) rather than funding a traditional hypothesis-driven research project.
How is this opportunity connected to the Alzheimers Disease Sequencing Project (ADSP)?
It is closely tied to ADSP, a large coordinated genomic sequencing effort designed to discover genetic variants influencing risk for Alzheimer disease and Alzheimer disease-related dementias (AD/ADRD). The supported family-based resource is positioned to feed into ADSP sequencing and downstream analyses.
What population or cohort does this opportunity focus on?
It focuses on families in which multiple relatives are affected by Alzheimer disease and related dementias (multiply affected families), which are particularly valuable for genetic discovery.
Why are multiply affected families valuable for genetic discovery?
Because patterns of disease across relatives can help identify inherited risk factors, interpret rare genetic variants, and refine genetic signals that might be harder to detect in unrelated case-control datasets.
What kinds of activities does the funding support?
The funding supports infrastructure and operations for collecting and managing high-value family-based data and biospecimens, expanding the existing sample set, and maintaining the ability to conduct longitudinal follow-up and re-contact participants over time.
Does the FOA expect applicants to start a new cohort from scratch?
No. The FOA emphasizes expanding the existing NIA Late Onset of AD Family Based Study sample set by adding informative relatives and deepening the dataset rather than initiating an entirely new cohort.
What does "longitudinal follow-up" mean in the context of this FOA?
It refers to repeated contact and data updates over time, including tracking outcomes and updating clinical and cognitive information as participants age and as diagnoses or status changes occur.
Why is longitudinal follow-up important for late-onset Alzheimer disease research?
Alzheimer disease develops over many years, and repeated measurements can help identify early signals, characterize progression patterns, and clarify differences between Alzheimer disease and other dementia syndromes.
What are "antecedent risk factors" as described in this opportunity?
They are exposures and characteristics that occur before dementia onset and may influence risk or resilience, such as medical history, cardiovascular and metabolic factors, lifestyle variables, and other relevant background information.
What does the FOA mean by characterizing additional relatives?
It means identifying and enrolling more family members beyond original participants, gathering pedigree information, documenting affected and unaffected status, and ensuring phenotypic details are sufficient for genetic analyses.
Are unaffected relatives important to include?
Yes. Unaffected older individuals in high-risk families can help identify potential protective factors and improve within-family (segregation) analyses.
Is this funding intended to support a clinical trial?
No. The FOA explicitly states "Clinical Trial Not Allowed," indicating the award is not intended for interventional clinical trial activities. The scope is infrastructure and observational follow-up rather than testing treatments or assigning interventions.
What does "Limited Competition" mean for this opportunity?
It means eligibility was restricted to a defined set of applicants described in the full announcement. The listing notes "Others" with clarification in the eligibility text.
How many awards were anticipated?
NIH anticipated making one award.
What was the maximum award amount mentioned (award ceiling)?
The award ceiling listed was $2,400,000.
What is the CFDA number associated with this opportunity?
The CFDA listing associated with this opportunity is 93.866.
What is the activity category for this program?
The program fell under the health activity category.
When was the FOA created and when did it close?
The FOA was created on December 14, 2020, and had an original closing date of February 17, 2021.
What is the overall expected outcome of the funded effort?
The expected outcome is a sustained and expanded operational backbone for the NIA late-onset Alzheimer family-based cohort, including ongoing participant engagement, broader participation within informative families, updated high-quality clinical and risk-factor data, and an enhanced resource that accelerates genetic discovery and related analyses across the Alzheimer research community.
Browse more opportunities from the same category: Health
Next opportunity: Advancing Arthritis Public Health Priorities through National Organizations
Previous opportunity: Combating Illegal Wildlife Trafficking
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA AG 22 001
Applicants also applied for:
Applicants who have applied for this opportunity (RFA AG 22 001) also looked into and applied for these:
| Funding Opportunity |
|---|
| National Center for Child Traumatic Stress – Category I, National Center for Child Traumatic Stress Cooperative Agreement Apply for SM 21 008 Funding Number: SM 21 008 Agency: Department of Health and Human Services, Substance Abuse and Mental Health Services Adminis Category: Health Funding Amount: $6,000,000 |
| National Child Traumatic Stress Initiative – Category II, Treatment and Service Adaptation (TSA) Centers Apply for SM 21 009 Funding Number: SM 21 009 Agency: Department of Health and Human Services, Substance Abuse and Mental Health Services Adminis Category: Health Funding Amount: $17,853,000 |
| Engaging the dental workforce to end the HIV epidemic in the U.S. (UG3/UH3 Clinical Trial Required) Apply for RFA DE 21 002 Funding Number: RFA DE 21 002 Agency: Department of Health and Human Services, National Institutes of Health Category: Health Funding Amount: Case Dependent |
| National Child Traumatic Stress Initiative – Category III, Community Treatment and Service (CTS) Centers Apply for SM 21 010 Funding Number: SM 21 010 Agency: Department of Health and Human Services, Substance Abuse and Mental Health Services Adminis Category: Health Funding Amount: $24,903,000 |
| Primary Care Training and Enhancement-Community Prevention and Maternal Health (PCTE-CPMH) Apply for HRSA 21 014 Funding Number: HRSA 21 014 Agency: Department of Health and Human Services, Health Resources and Services Administration Category: Health Funding Amount: $600,000 |
| Native Hawaiian Health Care Improvement Act Apply for HRSA 21 009 Funding Number: HRSA 21 009 Agency: Department of Health and Human Services, Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Enhancing Public Health Laboratory Capabilities and Increasing Capacity Apply for CDC RFA OE20 20010101SUPP21 Funding Number: CDC RFA OE20 20010101SUPP21 Agency: Department of Health and Human Services, Centers for Disease Control - CSELS Category: Health Funding Amount: $3,000,000 |
| Building Communities of Recovery Apply for TI 21 004 Funding Number: TI 21 004 Agency: Department of Health and Human Services, Substance Abuse and Mental Health Services Adminis Category: Health Funding Amount: $3,913,423 |
| Project AWARE (Advancing Wellness and Resiliency in Education) State Education Agency Grants Apply for SM 21 006 Funding Number: SM 21 006 Agency: Department of Health and Human Services, Substance Abuse and Mental Health Services Adminis Category: Health Funding Amount: $9,943,394 |
| Resiliency In Communities After Stress and Trauma Apply for SM 21 012 Funding Number: SM 21 012 Agency: Department of Health and Human Services, Substance Abuse and Mental Health Services Adminis Category: Health Funding Amount: $6,925,509 |
| PEPFAR Community-Led Monitoring Program Apply for DOS ANGOLA PEPFAR FY21 01 Funding Number: DOS ANGOLA PEPFAR FY21 01 Agency: Department of State, U.S. Mission to Angola Category: Health Funding Amount: $160,000 |
| Service Area Competition Apply for HRSA 21 008 Funding Number: HRSA 21 008 Agency: Department of Health and Human Services, Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Rural Emergency Medical Services Training Grant Apply for TI 21 005 Funding Number: TI 21 005 Agency: Department of Health and Human Services, Substance Abuse and Mental Health Services Adminis Category: Health Funding Amount: $5,000,000 |
| Elimination of lymphatic filariasis and elimination and control of other neglected tropical diseases (NTDs) in an effort to improve the quality and coverage of local programs. Apply for CDC RFA GH21 2104 Funding Number: CDC RFA GH21 2104 Agency: Department of Health and Human Services, Centers for Disease Control - CGH Category: Health Funding Amount: Case Dependent |
| State Pilot Grant Program for Treatment for Pregnant and Postpartum Women Apply for TI 21 002 Funding Number: TI 21 002 Agency: Department of Health and Human Services, Substance Abuse and Mental Health Services Adminis Category: Health Funding Amount: $3,000,000 |
| Tribal Opioid Response Grants Apply for TI 21 007 Funding Number: TI 21 007 Agency: Department of Health and Human Services, Substance Abuse and Mental Health Services Adminis Category: Health Funding Amount: $37,647,916 |
| Partnering and Communicating Together Apply for CDC RFA PS21 2104 Funding Number: CDC RFA PS21 2104 Agency: Department of Health and Human Services, Centers for Disease Control - NCHHSTP Category: Health Funding Amount: Case Dependent |
| Ryan White HIV/AIDS Program Part F Dental Reimbursement Program Apply for HRSA 21 056 Funding Number: HRSA 21 056 Agency: Department of Health and Human Services, Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Using Innovative Intervention Strategies to Improve Health Outcomes among People with HIV - Evaluation Center Apply for HRSA 21 068 Funding Number: HRSA 21 068 Agency: Department of Health and Human Services, Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Using Innovative Intervention Strategies to Improve Health Outcomes among People with HIV - Coordinating Center Apply for HRSA 21 076 Funding Number: HRSA 21 076 Agency: Department of Health and Human Services, Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA AG 22 001", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.